DMAC2

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, DMAC2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated DMAC2 data layer compared with 20 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher DMAC2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DMAC2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SKCM and UCEC are the cancer types where DMAC2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
SKCMOSMedianAll0.1970.789<.00132view →
UCECDFSMedianAll1.0000.629.0236view →
Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

DMAC2–SKCM (OS)

Kaplan–Meier survival curve for DMAC2 mutant vs wild-type samples in SKCM.

Open the SKCM breakdown →

Exploration